Reissig, Timm M. http://orcid.org/0000-0002-9955-5991
Uhrig, Sebastian
Jost, Philipp J.
Luchini, Claudio
Vicentini, Caterina
Liffers, Sven-Thorsten
Allgäuer, Michael
Adsay, Volkan
Scarpa, Aldo
Lawlor, Rita Teresa
Fröhling, Stefan
Stenzinger, Albrecht
Klöppel, Günter
Schildhaus, Hans-Ulrich http://orcid.org/0000-0002-9856-7050
Siveke, Jens T. http://orcid.org/0000-0002-8772-4778
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (SFB 1335 (Project-ID 360372040), SI1549/3-1 (Clinical Research Unit KFO337), SI1549/4-1)
Deutschen Konsortium für Translationale Krebsforschung
Deutsche Krebshilfe (#70112505/PIPAC, #70113834/PREDICT-PACA)
Wilhelm Sander-Stiftung (2019.008.1)
Deutsches Krebsforschungszentrum (grant 021)
Nationales Centrum für Tumorerkrankungen Heidelberg (Molecular Diagnostics Program)
Associazione Italiana per la Ricerca sul Cancro (AIRC 5x1000 n. 12182)
Fondazione Cassa di Risparmio di Verona Vicenza Belluno e Ancona (prot. 203885/2017)
Ministero della Salute (RF CO-2019-12369662: CUP: B39C21000370001)
Universitätsklinikum Essen
Article History
Received: 7 December 2021
Revised: 26 April 2022
Accepted: 23 May 2022
First Online: 7 June 2022
Declarations
:
: Patients of the NCT/DKTK MASTER cohort gave written informed consent under protocol S-206/2011, which has been approved by the Ethics Committee of the University of Heidelberg. The present study was approved by the local Ethics Committee of the University Duisburg-Essen (20–9337-BO).
: PJJ: Abbvie, Ariad, Bayer, Boehringer, Janssen (Johnson and Johnson), Novartis, Pfizer, Servier, Roche, BMS/Celgene (consulting or advisory role); Abbvie, Ariad, Bayer, Boehringer, Janssen (Johnson and Johnson), Novartis, Pfizer, Servier, Roche, BMS/Celgene (honoraria); Abbvie, Boehringer, Novartis, Roche, BMS/Celgene (research funding); Bayer, Boehringer, Janssen (Johnson and Johnson), MSD, Novartis, Pfizer, Pierre Fabre, Servier, Roche, BMS/Celgene (online registration/travel/accommodation).SF: Consulting or advisory board membership: Bayer, Illumina, Roche; honoraria: Amgen, Eli Lilly, PharmaMar, Roche; research funding: AstraZeneca, Pfizer, PharmaMar, Roche; travel or accommodation expenses: Amgen, Eli Lilly, Illumina, PharmaMar, Roche.ASt: Advisory Board/Speaker’s Bureau: Astra Zeneca, AGCT, Bayer, BMS, Eli Lilly, Illumina, Janssen, MSD, Novartis, Pfizer, Roche, Seattle Genetics, Takeda, Thermo Fisher. Grants: Bayer, BMS, Chugai.HUS: Targos Molecular Pathology, Inc. (employment); Roche, Novartis Oncology, MSD, BMS, Pfizer, ZytoVision, Zytomed (honoraria); AstraZeneca, Agilent, Molecular Health, MSD (advisory boards); Novartis Oncology (research funding—outside of this study).JTS: Bristol-Myers Squibb, Celgene, Roche (research funding—outside of this study); AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Immunocore, Novartis, Roche, Shire (consulting or advisory role); AstraZeneca, Aurikamed, Baxalta, Bristol-Myers Squibb, Celgene, Falk Foundation, iomedico, Immunocore, Novartis, Roche, Shire (honoraria); minor equity in iTheranostics and Pharma15 and member of the Board of Directors for Pharma15 outside the submitted work.All remaining authors declare no conflicts of interest.